Stock listing

BX Swiss:EVMN Evommune, Inc. Aktie

Swiss listing (BX Swiss) of Evommune, Inc. · home listing NYSE:EVMN

Follow Evommune, Inc. into a list and get an email when it puts out news.

Home listing price · NYSE:EVMN

$7.04 USD +0.16 (+2.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:EVMN

Past year -62.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.96 – $7.24 USDNov 20, 2026
Volume
549,397 sharesNov 20, 2026
Market cap
$255.5M USDAt the close on Nov 20, 2026 · price × 36.29M shares outstanding
52-week range
$4.94 – $33.20 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$6.76M USDMedian day 594,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Evommune, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:EVMN · Home$7.04 USD+0.16 (+2.3%)549,397$7.10$7.24$6.96$6.88Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:EVMN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.04+0.16+2.3%$7.10$7.24$6.96549,397
$6.88-0.14-2.0%$6.89$7.21$6.74600,346
$7.02-0.08-1.1%$7.10$7.19$6.799901,868
$7.10-0.53-6.9%$7.54$7.77$7.07671,350
$7.63-0.39-4.9%$8.18$8.18$7.445723,350
$8.02-0.60-7.0%$8.58$8.58$7.7351,141,350
$8.62+0.78+9.9%$7.90$8.92$7.791,432,904
$7.84+0.19+2.5%$7.48$8.09$7.405843,158
$7.65+1.00+15.0%$6.82$7.87$6.73823,671
$6.65+0.28+4.4%$6.45$6.79$6.27455,040
$6.37+0.33+5.5%$6.65$7.15$6.341,021,795
$6.04+0.10+1.7%$6.11$6.30$5.82227,250
$5.94-0.07-1.2%$6.03$6.11$5.865211,528
$6.01-0.72-10.7%$6.75$6.815$5.89726,325
$6.73-0.08-1.2%$6.65$6.84$6.29586,144
$6.81+0.50+7.9%$6.38$7.174$6.281,154,441
$6.31+1.15+22.3%$5.50$7.21$5.356,509,437
$5.16+0.03+0.6%$5.13$5.26$4.961,301,850
$5.13+0.03+0.6%$5.10$5.31$5.02322,214
$5.10-0.11-2.1%$5.18$5.18$4.94280,527
$5.21+0.04+0.8%$5.13$5.365$5.095255,756
$5.17-0.21-3.9%$5.41$5.521$5.125383,385
$5.38+0.11+2.1%$5.33$5.70$5.33382,462
$5.27+0.10+1.9%$5.30$5.43$5.125422,783
$5.17-0.76-12.8%$5.97$6.00$5.09986,400
$5.93+0.16+2.8%$5.90$6.00$5.81579,100
$5.77-0.11-1.9%$5.79$5.96$5.64574,800
$5.88-0.17-2.8%$6.05$6.05$5.85804,900
$6.05-0.20-3.2%$6.09$6.22$6.04384,000
$6.25-0.16-2.5%$6.40$6.44$6.175558,000
$6.41+0.19+3.1%$6.18$6.44$6.02692,000
$6.22-0.39-5.9%$6.51$6.525$6.152,112,500
$6.61-0.04-0.6%$6.67$6.67$6.081,007,400
$6.65-0.27-3.9%$6.86$7.216$6.521,365,200
$6.92-0.29-4.0%$7.25$7.28$6.741,745,400
$7.21-1.05-12.7%$8.25$8.30$6.991,524,900
$8.26-0.09-1.1%$8.40$8.525$8.11720,200
$8.35-0.04-0.5%$8.36$8.65$8.11807,600
$8.39-0.10-1.2%$8.40$8.435$8.12660,800
$8.49-0.31-3.5%$8.78$8.78$8.33541,100
$8.80+0.03+0.3%$8.73$8.90$8.25992,200
$8.77-0.83-8.6%$9.48$9.54$8.69872,400
$9.60+0.15+1.6%$9.45$9.865$9.392573,800
$9.45-0.20-2.1%$9.70$9.70$9.35603,000
$9.65+0.28+3.0%$9.39$9.75$9.201,494,000
$9.370.000.0%$9.57$9.67$9.35405,805
$9.37-0.62-6.2%$9.98$9.99$9.301568,800
$9.99-0.44-4.2%$10.43$10.43$9.80520,000
$10.43-0.11-1.0%$10.49$10.63$10.31350,200
$10.54-0.02-0.2%$10.66$10.82$10.50388,900
$10.56-0.28-2.6%$10.50$11.03$10.31692,400
$10.84-2.24-17.1%$11.90$12.10$10.303,986,300
$13.08+0.81+6.6%$12.11$13.35$12.011,235,800
$12.27+0.27+2.2%$11.87$12.46$11.87249,100
$12.00-0.48-3.8%$12.70$12.70$11.70594,200
$12.480.000.0%$12.50$12.80$12.33366,100
$12.48-0.18-1.4%$12.50$12.74$12.42278,500
$12.66-0.57-4.3%$13.08$13.13$12.61571,900
$13.23-0.25-1.9%$13.48$13.65$12.97350,600
$13.48-0.63-4.5%$14.13$14.18$13.41252,500
$14.11+0.32+2.3%$14.17$14.28$13.59342,100
$13.79+0.12+0.9%$13.79$14.44$13.60340,400
$13.67-0.35-2.5%$13.91$13.91$13.03228,600
$14.02+0.45+3.3%$13.74$14.25$13.70326,500
$13.57-1.44-9.6%$14.76$14.76$13.20764,800
Ticker
BX Swiss:EVMN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BX Swiss
Currency
CHF

What changed lately

Latest news

All Evommune, Inc. news

Evommune, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 17 in all · newest Nov 12, 2026 · oldest 2025
Decks
12 decks · latest Nov 12, 2026

Where Evommune, Inc. is listed

ListingExchangeCountryCurrency
NYSE:EVMN · Home listingNYSEUnited StatesUSD
BX Swiss:EVMN · This pageBX SwissSwitzerlandCHF
BOATS:EVMNBOATSUnited StatesUSD
BX Swiss:EVMNUSDBX SwissSwitzerlandUSD

Valuation

Price/book 1.0× against a median of 2.0×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$86.86M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.96

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.5MUS$243.4Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.4Mn/an/an/a2.0×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Q32 Bio Inc. · NASDAQ:QTTBUS$249.6M−US$35.66M7.7×−0.7×−1.9×0.9×59.8%0.0×0.59
Median of the othersUS$257.8MUS$128.0M7.7×6.3×−1.9×2.0×−144.9%0.1×1.48

Forecasts

5 strong buy · 4 buy · 3 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
22.22 USD · Analysts' mean
EPS, year to Dec 2026
-3.39 · 7 analysts

Team and board

Officers

OfficerRole
Luis PeñaExecutive Director, President & Chief Executive Officer
Kyle CarverChief Financial Officer
Megan HumphreysVice President, Corporate Communications
Andrea KimVice President, Nonclinical Development
J. Mark JacksonSenior Vice President, Clinical Development
Lou SehlSenior Vice President, Technical Operations
Eugene A. BauerExecutive Director, Chief Medical Officer
Gregory S. MossChief Business and Legal Officer
Janice DrewChief of Development Operations
Jeegar PatelChief Scientific Officer

Board

DirectorRole
Benjamin F. McGrawChair of Board
Arthur KirschAudit
David E. CohenCompensation
Derek DiRoccoBoard Member
Eugene A. BauerExecutive Director, Chief Medical Officer
Felice Verduyn-van WeegenNominating and Corporate Governance
Gregory S. MossChief Business and Legal Officer
Jeegar PatelChief Scientific Officer
Kyle CarverChief Financial Officer
Luis PeñaExecutive Director, President & Chief Executive Officer
Rob HopfnerAudit

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−4.9%
Q2 2026Aug 6, 2026 · After close+5.2%
Q1 2026May 8, 2026+3.2%
Q4 2025Mar 5, 2026 · After close+5.6%
Q3 2025Dec 11, 2025 · After close−8.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck61 slidesNov 12, 2026
Corporate Update (November 2026)Corporate update20 slidesNov 4, 2026
Investor Presentation (October 2026)Investor deck47 slidesOctober 2026
European Academy of Dermatology and Venereology Annual Meeting 2026Conference10 slidesOct 1, 2026
Investor Presentation (September 2026)Investor deck39 slidesSep 15, 2026
Investor Presentation (September 2026)Investor deck42 slidesSeptember 2026
American Headache Society (AHS) Annual Scientific Meeting (June 2026)Conference14 slidesJune 2026
Investor Presentation (May 2026)Investor deck62 slidesMay 7, 2026
Technical Presentation (April 2026)Technical36 slidesApr 13, 2026
Investor Presentation (March 2026)Investor deck50 slidesMar 5, 2026
All 12 decks
DeckKindSlidesDate
Technical Presentation (February 2026)Technical27 slidesFeb 10, 2026
Technical Presentation (November 2024)Technical12 slidesNov 22, 2024

Open Decks

Financings

RaiseDate
Private placement of common stock
Announced: about US$125M · US$27.88 a share · Morgan Stanley & Co. LLC +5
Dealers: Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., William Blair & Company, L.L.C., Oppenheimer & Co. Inc.
Use of proceeds: To advance its clinical development programs and for general corporate purposes
Feb 13, 2026
Public offering of common stock
Update: US$150M · US$16 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), Cantor (co-lead)
Nov 6, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Nov 5, 2025.

Price
US$16.00 a share
Shares offered
9,375,000 shares of common stock
Offering size
US$150 million
Underwriters' option
Up to 1,406,250 more shares
Listing
EVMN on the New York Stock Exchange
Underwriters
MORGAN STANLEY, LEERINK PARTNERS, EVERCORE ISI, CANTOR · In the order on the cover
Shares delivered
On or about Nov 7, 2025

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2025
Filed publiclyOct 9, 2025
Amended onceOct 17, 2025
Shares registered with an exchangeNov 4, 2025
Final prospectus, with the priceNov 6, 2025

Open IPO · From the cover of the final prospectus (424B4) filed Nov 6, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue13.0M7.00M5.00M
Cost of revenue1.39M1.29M1.00M
Gross profit13.0M5.71M4.00M
Research and development74.0M64.2M32.0M
Selling, general and administrative20.0M
Operating income-81.1M-70.0M-37.9M
Depreciation and amortization600.0K500.0K1.00M
EBITDA-80.5M-69.5M-36.9M
Interest expense7.00K34.0K58.0K
Income before tax-68.9M-68.3M-34.1M
Income tax00
Net income-68.9M-66.8M-34.1M
Earnings per share, basic-11.22-45.29-1.13
Earnings per share, diluted-11.22-45.29

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents44.1M16.3M29.0M
Short-term investments105.1M55.8M50.1M
Current assets153.5M74.0M80.0M
Property, plant and equipment994.0K1.33M
Total assets224.9M76.1M82.2M
Accounts payable7.76M8.26M1.76M
Current liabilities17.9M28.0M6.86M
Total debt1.71M193.3M150.6M
Total liabilities19.4M28.5M160.0M
Shareholders' equity205.6M-144.2M-77.7M
Shares outstanding31.5M1.55M30.1M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-76.4M-58.2M-30.0M
Capital spending-235.0K-88.0K-118.0K
Free cash flow-76.7M-58.3M-30.1M
Cash from investing-115.3M-3.99M-48.4M
Cash from financing220.8M49.4M63.8M
Change in cash29.0M-12.8M29.0M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
424B3 · ProspectusNov 17, 2026Offer documentSEC
All 155 filings
FilingDateTypeFiled with
8-K · Current reportNov 17, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
424B3 · ProspectusNov 12, 2026Offer documentSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
8-K · Current reportNov 5, 2026Current reportSEC
424B3 · ProspectusNov 4, 2026Offer documentSEC
8-K · Current reportNov 4, 2026Material contractSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
8-K · Current reportOct 1, 2026Current reportSEC
8-K · Current reportSep 23, 2026Current reportSEC
8-K · Current reportSep 15, 2026Current reportSEC
424B3 · ProspectusSep 8, 2026Offer documentSEC
8-K · Current reportSep 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
424B3 · ProspectusAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
8-K · Current reportJul 30, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 16, 2026Big-stake noticeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
424B3 · ProspectusJun 29, 2026Offer documentSEC
8-K · Current reportJun 29, 2026Current reportSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
424B3 · ProspectusJun 2, 2026Offer documentSEC
8-K · Current reportJun 2, 2026Meeting outcomeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
424B3 · ProspectusMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveApr 27, 2026Other filingsSEC
424B3 · ProspectusApr 24, 2026Offer documentSEC
CORRESP · Letter to the SECApr 22, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 22, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
S-1 · Registration statementApr 17, 2026Offer documentSEC
8-K · Current reportApr 13, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 19, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 13, 2026Material contractSEC
8-K · Current reportFeb 10, 2026Current reportSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
10-Q · Quarterly reportDec 11, 2025Quarterly reportSEC
8-K · Current reportDec 11, 2025ResultsSEC
SCHEDULE 13D · Big-stake noticeNov 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 17, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
S-8 · Registration statement for employee plansNov 7, 2025Offer documentSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
4 · Change in ownershipNov 7, 2025Insider tradeSEC
8-K · Current reportNov 7, 2025Current reportSEC
424B4 · ProspectusNov 6, 2025Offer documentSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
FWP · Free writing prospectusNov 5, 2025Offer documentSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2025Insider tradeSEC
CERT · Exchange's certificate of listingNov 5, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeNov 4, 2025Other filingsSEC
FWP · Free writing prospectusOct 30, 2025Offer documentSEC
S-1/A · Registration statement, amendedOct 17, 2025Offer documentSEC
S-1 · Registration statementOct 9, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftSep 22, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedSep 22, 2025Offer documentSEC
UPLOAD · Letter from the SECSep 10, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftAug 29, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedAug 29, 2025Offer documentSEC
UPLOAD · Letter from the SECJul 30, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftJul 18, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedJul 18, 2025Offer documentSEC
UPLOAD · Letter from the SECJun 10, 2025Other filingsSEC
DRS · Draft registration statementMay 14, 2025Offer documentSEC
DJan 8, 2025Other filingsSEC
DJan 7, 2025Other filingsSEC
DJan 7, 2025Other filingsSEC
DJan 6, 2025Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Evommune, Inc.’s releases · as of Feb 13, 2026

Common shares
36,292,113
Fully diluted
36,292,113

Fully diluted

LineShares
Common shares36,292,113

Share count over time

CountShares
Nov 22, 202636,292,113

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
EQT Fund Management S.a r.l.5.29M12.8%US$43.7MSep 30, 2026
Ra Capital Management, L.P.3.49M8.5%US$28.9MSep 30, 2026
Point72 Asset Management, L.P.2.43M5.9%US$20.1MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC1.93M4.7%US$15.9MSep 30, 2026
Nan Fung Group Holdings Ltd1.44M3.5%US$11.9MSep 30, 2026
Defilade Capital Management, L.P.1.43M3.5%US$11.8MSep 30, 2026
Vanguard1.3M3.1%US$10.8MSep 30, 2026
Vestal Point Capital, LP1.25M3.0%US$10.3MSep 30, 2026
Baker Bros. Advisors LP1.23M3.0%US$10.2MSep 30, 2026
Kynam Capital Management, LP1.2M2.9%US$9.91MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
BlackRock1.15M2.8%US$9.53MSep 30, 2026
T. Rowe Price852K2.1%US$7.04MSep 30, 2026
Millennium847K2.0%US$7MSep 30, 2026
American Century762K1.8%US$6.3MSep 30, 2026
Qube Research & Technologies Ltd685K1.7%US$5.66MSep 30, 2026
Silverarc Capital Management, LLC594K1.4%US$4.91MSep 30, 2026
Barclays527K1.3%US$4.35MSep 30, 2026
Geode Capital467K1.1%US$3.86MSep 30, 2026
Velan Capital Investment Management LP456K1.1%US$3.77MSep 30, 2026
Sphera Funds Management LTD.391K0.94%US$3.23MSep 30, 2026
Citadel380K0.92%US$3.14MSep 30, 2026
Jane Street330K0.80%US$2.73MSep 30, 2026
Great Point Partners LLC325K0.79%US$2.68MSep 30, 2026
Goldman Sachs301K0.73%US$2.49MSep 30, 2026
Trexquant Investment LP285K0.69%US$2.35MSep 30, 2026
State Street268K0.65%US$2.21MSep 30, 2026
Two Sigma260K0.63%US$2.15MSep 30, 2026
Cantor Fitzgerald, L. P.258K0.62%US$2.13MSep 30, 2026
BNP Paribas244K0.59%US$2.01MSep 30, 2026
Rtw Investments, LP208K0.50%US$1.72MSep 30, 2026
SummitTX Capital, L.P.202K0.49%US$1.67MSep 30, 2026
Fidelity169K0.41%US$1.39MSep 30, 2026
XTX Topco Ltd167K0.40%US$1.38MSep 30, 2026
Orbimed Advisors LLC161K0.39%US$1.33MSep 30, 2026
Y-Intercept (Hong Kong) Ltd159K0.38%US$1.31MSep 30, 2026
Nuveen158K0.38%US$1.31MSep 30, 2026
Schwab151K0.36%US$1.25MSep 30, 2026
Northern Trust137K0.33%US$1.13MSep 30, 2026
Hrt Financial LP127K0.31%US$1.05MSep 30, 2026
NEXTBio Capital Management LP119K0.29%US$983KSep 30, 2026
D. E. Shaw & Co., Inc.99,9440.24%US$826KSep 30, 2026
Andera Partners97,3620.24%US$804KSep 30, 2026
Morgan Stanley94,5730.23%US$781KSep 30, 2026
Jump Financial, LLC84,0230.20%US$694KSep 30, 2026
ADAR1 Capital Management, LLC82,3500.20%US$680KSep 30, 2026
Squarepoint Ops LLC79,6960.19%US$658KSep 30, 2026
Walleye Capital LLC78,9670.19%US$652KSep 30, 2026
Marshall Wace, LLP76,8110.19%US$634KSep 30, 2026
Seven Grand Managers, LLC50,0000.12%US$413KSep 30, 2026
Algert Global LLC48,8140.12%US$403KSep 30, 2026

This page holds 50 of 101 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Eventide Healthcare & Life Sciences Fund940K2.3%US$12.5MJun 30, 2026
Vanguard Total Stock Market Index Fund739K1.8%US$9.82MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.711K1.7%US$9.45MJun 30, 2026
Small Cap Growth Fund568K1.4%US$6.39MJul 31, 2026
JPMorgan Small Cap Growth Fund554K1.3%US$7.37MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.347K0.84%US$4.61MJun 30, 2026
iShares Russell 2000 ETF332K0.80%US$4.41MJun 30, 2026
Federated Hermes Kaufmann Small Cap Fund325K0.79%US$3.66MJul 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund258K0.62%US$3.43MJun 30, 2026
JPMorgan Small Cap Blend Fund176K0.43%US$2.34MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Small Cap Index Fund139K0.34%US$1.56MJul 31, 2026
Vanguard Extended Market Index Fund127K0.31%US$1.68MJun 30, 2026
iShares Russell 2000 Growth ETF119K0.29%US$1.58MJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund92,6840.22%US$2.15MMay 31, 2026
Fidelity Extended Market Index Fund58,0330.14%US$1.35MMay 31, 2026
Vanguard Russell 2000 Index Fund53,8770.13%US$1.25MMay 31, 2026
Schwab U.S. Small-Cap ETF53,2640.13%US$1.24MMay 31, 2026
iShares Micro-Cap ETF42,6500.10%US$567KJun 30, 2026
T. Rowe Price Small-Mid Cap ETF40,6400.10%US$540KJun 30, 2026
Small Cap Growth Fund38,4990.09%US$894KMay 31, 2026
Schwab Small-Cap Index Fund30,8300.07%US$347KJul 31, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund29,8660.07%US$397KJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio25,2000.06%US$335KJun 30, 2026
T. Rowe Price Health Sciences Portfolio23,9150.06%US$318KJun 30, 2026
Master Small Cap Index Series23,6990.06%US$315KJun 30, 2026
Fidelity Total Market Index Fund20,4170.05%US$474KMay 31, 2026
Small Company Growth Portfolio19,5150.05%US$259KJun 30, 2026
Transamerica T. Rowe Price Small Cap VP18,9000.05%US$251KJun 30, 2026
Fidelity Series Total Market Index Fund17,0180.04%US$395KMay 31, 2026
Nuveen Small Cap Blend Index Fund16,8610.04%US$190KJul 31, 2026
Virtus Biotech Clinical Trials Etf15,6740.04%US$176KJul 31, 2026
Blackstone Alternative Multi-Strategy Fund15,3680.04%US$204KJun 30, 2026
EQ/2000 Managed Volatility Portfolio13,8710.03%US$184KJun 30, 2026
Schwab Total Stock Market Index Fund12,0000.03%US$135KJul 31, 2026
Fidelity Small Cap Growth Index Fund11,8800.03%US$158KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund9,8140.02%US$130KJun 30, 2026
LVIP State Street Small-Cap Index Fund9,3000.02%US$124KJun 30, 2026
Health Sciences Trust8,2010.02%US$109KJun 30, 2026
EQ/AB Small Cap Growth Portfolio8,1800.02%US$109KJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund7,0360.02%US$79,155Jul 31, 2026
Small Cap Index Fund6,5350.02%US$86,850Jun 30, 2026
Vanguard Balanced Index Fund6,4640.02%US$85,907Jun 30, 2026
Column Small Cap Fund6,1940.01%US$144KMay 31, 2026
Global X Russell 2000 ETF6,0730.01%US$68,321Jul 31, 2026
Schwab U.S. Broad Market ETF6,0000.01%US$139KMay 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio5,9330.01%US$78,850Jun 30, 2026
iShares Morningstar Small-Cap Growth ETF5,8470.01%US$65,779Jul 31, 2026
Fidelity ZERO Total Market Index Fund5,7570.01%US$64,766Jul 31, 2026
ATM Small Cap Managed Volatility Portfolio5,2730.01%US$70,078Jun 30, 2026
EQ/Small Company Index Portfolio5,1400.01%US$68,311Jun 30, 2026

This page holds 50 of 116 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Carver Kyle
Officer: Chief Financial Officer
Buy1,000USD 13.26US$13,260Jul 8, 2026
Kirsch Arthur S
Director
Buy10,000USD 13.30US$133KJul 7, 2026
Pena Luis C.
Director, Officer: President & CEO
Sale7,438USD 22.71US$169KJun 22, 2026
Drew Janice Suzann
Officer: Chief of Dev. Operations
Sale20,000USD 22.63US$453KJun 22, 2026
Patel Jeegar Pravinkumar
Officer: Chief Scientific Officer
Sale1,488USD 22.50US$33,480Jun 22, 2026
Cohen David E
Director
Sale5,456USD 20.21US$110KJun 2, 2026
Cohen David E
Director
Sale600USD 21.38US$12,828Jun 2, 2026
Pena Luis C.
Director, Officer: President & CEO
Sale16,787USD 22.74US$382KJun 1, 2026
Patel Jeegar Pravinkumar
Officer: Chief Scientific Officer
Sale16,687USD 22.74US$379KJun 1, 2026
Moss Gregory S.
Officer: Chief Business & Legal Officer
Sale14,223USD 22.83US$325KMay 28, 2026
All 11 trades
TradeTradeSharesPriceValueDate
Carver Kyle
Officer: Chief Financial Officer
Sale18,175USD 22.84US$415KMay 28, 2026

Big stakes

StakeStakeSharesDateFiling
LSP 7 Cooperatieve U.A.14.70%5.29MFeb 12, 2026Schedule 13D
Nan Fung Group Holdings Limited10.90%3.44MDec 31, 2025Schedule 13G
Ra Capital Management, L.P.8.50%3.49MNov 6, 2026Schedule 13D
Point72 Asset Management, L.P.6.70%2.43MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Nov 5, 2025
Arthur Kirsch
Other companies: Atea Pharmaceuticals, Inc. (Director · Since at least Feb 20, 2025); Liquidia Corporation (Board Member · Since at least Mar 24, 2021); Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past); Aralez Pharmaceuticals Inc (Director · May 12, 2016 – Dec 8, 2017 · Past)
Audit · Since at least Nov 5, 2025
Derek DiRocco
Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); Acrivon Therapeutics, Inc. (Director · Since at least May 18, 2026)
Board Member · Since at least Nov 4, 2026
Gregory S. Moss
Other companies: Anteris Technologies Global Corp. (Director · Since at least Jun 7, 2025); Kadmon Holdings Inc (EVP, Gen. Coun. / CCO. · Aug 30, 2019 – Nov 9, 2021 · Past)
Chief Business and Legal Officer · Since at least Nov 5, 2025
Benjamin F McGraw III
Other companies: Aerie Pharmaceuticals Inc. (Director · Jun 17, 2021 – Nov 21, 2022 · Past)
Director · Since at least Nov 5, 2025
David E. Cohen
Other companies: Timber Pharmaceuticals Inc (Director · Apr 15, 2022 – Apr 15, 2023 · Past)
Director · Since at least Nov 5, 2025
Eugene Bauer
Other companies: Kadmon Holdings Inc (Director · May 15, 2019 – Nov 9, 2021 · Past)
Executive Director, Chief Medical Officer · Since at least Nov 5, 2025
Andrea KimVice President, Nonclinical Development · Since at least Nov 4, 2026
Benjamin F. McGrawChair of Board · Since at least Nov 4, 2026
Felice Verduyn-van WeegenNominating and Corporate Governance · Since at least Nov 4, 2026
All 18 people
PersonSeat
Janice DrewChief of Development Operations · Since at least Jun 24, 2026
Jeegar PatelChief Scientific Officer · Since at least Nov 5, 2025
J. Mark JacksonSenior Vice President, Clinical Development · Since at least Nov 5, 2026
Kyle CarverChief Financial Officer · Since at least Nov 5, 2025
Lou SehlSenior Vice President, Technical Operations · Since at least Nov 4, 2026
Luis PeñaExecutive Director, President & Chief Executive Officer · Since at least Nov 5, 2025
Megan HumphreysVice President, Corporate Communications · Since at least Oct 1, 2026
Rob HopfnerAudit · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Evommune, Inc.